**Patients Urged Not to Discontinue Medication Following Remedica Recall**
The Pharmaceutical Services of Cyprus issued a crucial warning on Thursday, advising patients against discontinuing their medication after a recent recall by pharmaceutical company Remedica. The agency emphasized that halting treatment without professional guidance could lead to serious health consequences.
The recall, initiated by Remedica earlier this week, affects several batches of nine different pharmaceutical products. The company took this precautionary measure after stability studies revealed results that fell outside the specified limits. However, the Pharmaceutical Services clarified that the recall does not indicate any toxicity or harm associated with the affected medications.
“Patients should under no circumstances discontinue their treatment on their own,” the Pharmaceutical Services stated. They urged individuals to adhere strictly to the instructions provided by their healthcare providers and, if necessary, to seek replacement treatments as advised. The agency reassured patients that alternative medications containing the same active ingredients or suitable substitutes have been identified for most of the recalled products.
Among the medications recalled are Carvidex, a beta-blocker used for managing high blood pressure, angina, and heart failure, and Clonotril, which is primarily prescribed for seizure disorders and anxiety-related conditions. The recall has prompted healthcare professionals to adjust patients' prescriptions accordingly.
The timing of the recall has raised concerns, as many patients reported difficulties in contacting their doctors or local pharmacies due to closures ahead of the upcoming holiday. This situation has compounded the challenges faced by those requiring immediate access to alternative medications.
The Pharmaceutical Services reiterated that the recall was a precautionary action, conducted in compliance with safety regulations that govern the production and distribution of pharmaceuticals. They emphasized that such recalls are unpredictable and can occur at any time when stability issues are identified.
In light of these developments, patients are encouraged to remain proactive about their health. They should reach out to their healthcare providers for guidance on managing their treatment during this period. The Pharmaceutical Services assured the public that all necessary measures are being implemented to ensure continuity of care and minimize disruption to patients' treatment plans.
As the situation evolves, the agency will continue to monitor the impact of the recall and provide updates as needed. Patients are advised to stay informed and maintain open lines of communication with their healthcare providers to navigate this challenging time safely.